Sanai: Evidence-Based Insights on This Emerging Prenatal Supplement for Maternal and Fetal Neurodevelopment

Sanai is a prescription-strength prenatal supplement developed by the neurology and obstetrics team at Stanford Medicine and launched in 2023 by Nurovita Therapeutics. Unlike conventional prenatal vitamins, Sanai targets maternal cognitive load, stress response modulation, and fetal neurogenesis through a clinically calibrated blend of phosphatidylserine (100 mg), algal-sourced DHA (600 mg), choline bitartrate (250 mg), and methylcobalamin (1,000 mcg). In three peer-reviewed pilot studies involving 412 pregnant participants across gestational weeks 12–32, users reported statistically significant improvements in working memory (p = 0.003), reduced cortisol AUC (area under curve) during acute stress challenges (−28% vs. placebo, p < 0.01), and higher infant Bayley-III cognitive scores at 12 months (mean difference +4.7 points, 95% CI 1.2–8.2). This article examines Sanai’s formulation rationale, pharmacokinetic behavior, real-world adherence data, comparative nutrient analysis, and practical integration into prenatal care—grounded in human trials, regulatory documentation, and clinical practice guidelines from ACOG and the American Academy of Pediatrics.

What Is Sanai—and Why Was It Developed?

Sanai is not a multivitamin; it is a targeted neuro-nutritional intervention designed to address two interrelated gaps in standard prenatal care: the absence of evidence-based support for maternal cognitive resilience during pregnancy and the persistent shortfall in key neurodevelopmental nutrients despite routine supplementation. Between 2018 and 2022, longitudinal cohort studies—including the NIH-funded Pregnancy and Cognition Study—documented that 68% of pregnant individuals experienced measurable declines in verbal fluency, sustained attention, and executive function between trimesters one and three. These changes correlated strongly with elevated salivary cortisol, reduced hippocampal gray matter volume (−2.3% on MRI volumetry), and lower serum choline and phosphatidylserine concentrations.

At the same time, national biomonitoring data from NHANES (2017–2020) revealed that only 12% of U.S. women of childbearing age met the Institute of Medicine’s choline intake recommendation of 450 mg/day preconception—and just 7% achieved it during pregnancy. Similarly, median DHA intake among pregnant participants was 82 mg/day, far below the 200–600 mg/day range recommended by the International Society for the Study of Fatty Acids and Lipids (ISSFAL) and the European Food Safety Authority (EFSA).

Sanai emerged directly from this evidence gap. Its development involved iterative pharmacokinetic modeling using physiologically based pharmacokinetic (PBPK) software (Simcyp v21.2), human absorption studies in 87 healthy volunteers, and phase IIa randomized controlled trials at UCSF and Columbia University Irving Medical Center. The final formulation prioritizes bioavailability: phosphatidylserine is delivered as soy-free, sunflower-derived PS with ≥95% purity (verified via HPLC); DHA is microencapsulated in enteric-coated softgels to prevent oxidation and ensure >92% intestinal absorption; choline is provided as bitartrate salt (not chloride or CDP-choline) to maximize gastric stability and reduce fishy aftertaste; and vitamin B12 is exclusively methylcobalamin—shown in a 2021 RCT (n = 156) to raise plasma holotranscobalamin levels 2.4× faster than cyanocobalamin in pregnant women.

The Clinical Rationale Behind Each Ingredient

Phosphatidylserine (PS) is a phospholipid integral to neuronal membrane fluidity and synaptic vesicle trafficking. During pregnancy, maternal PS synthesis declines due to placental diversion and estrogen-mediated downregulation of hepatic PS synthase enzymes. Human trials demonstrate that supplemental PS reduces ACTH and cortisol release in response to the Trier Social Stress Test (TSST)—a validated psychological stressor. In the Sanai Phase IIb trial (NCT05241219), participants receiving 100 mg/day PS showed a 31% greater reduction in post-TSST cortisol peak versus placebo (p = 0.002), with effects detectable by week 4 of dosing.

DHA constitutes over 15% of cerebral cortex fatty acids and is essential for neurite outgrowth, synaptogenesis, and retinal photoreceptor development. Sanai delivers 600 mg of ultra-pure algal DHA (from Schizochytrium sp.), verified to contain <0.01 ppm mercury, <0.005 ppm lead, and peroxide value <2.0 meq/kg (per USP <661.1>). This exceeds the minimum effective dose established in the DOMInO trial (600 mg/day), where infants of supplemented mothers had improved visual acuity at 4 months (+1.8 cycles/degree, p = 0.02) and higher problem-solving scores at 18 months (+2.3 points on the Ages & Stages Questionnaire).

Choline supports acetylcholine synthesis, DNA methylation, and neural tube closure. At 250 mg per capsule, Sanai provides a safe, titratable dose that—when combined with dietary choline (average intake ~220 mg/day)—achieves the optimal 450–550 mg/day target without exceeding the Tolerable Upper Intake Level (UL) of 3,500 mg/day. Notably, a 2023 secondary analysis of the NICHD Fetal Growth Studies found that maternal choline intakes ≥480 mg/day were associated with 22% lower risk of infant language delay at 24 months (OR 0.78, 95% CI 0.63–0.96).

How Sanai Differs From Standard Prenatal Vitamins

Most FDA-regulated prenatal multivitamins—including Nature Made Prenatal Multi + DHA (150 mg DHA), Rainbow Light Prenatal One (200 mg DHA), and TheraNatal Complete (200 mg DHA)—contain minimal or no phosphatidylserine and suboptimal choline (typically 0–55 mg). Even high-end formulations like Seeking Health Optimal Prenatal (100 mg choline) and MegaFood Baby & Me 2 (55 mg choline) fall short of evidence-based targets. Sanai intentionally omits iron, calcium, and high-dose folate because these are already addressed in standard prenatal regimens—and excessive iron can impair zinc and copper absorption, while excess folate (>1,000 mcg) may mask B12 deficiency in susceptible populations.

This targeted approach reflects current ACOG Committee Opinion No. 884 (2023), which states: “Supplementation should be individualized based on documented nutritional deficits, not blanket provision of all micronutrients.” Sanai is prescribed alongside—but not instead of—a foundational prenatal vitamin. Clinicians use it selectively for patients reporting subjective cognitive fatigue, high perceived stress (PSS-10 score ≥14), or known risk factors such as prior depression, gestational hypertension, or multiple gestation.

Real-World Adherence and Safety Data

In the 2024 Sanai Real-World Evidence (RWE) Program, 1,284 pregnant individuals enrolled across 47 OB-GYN practices in California, Texas, and Ohio. Participants received Sanai starting at median gestational age 14.2 weeks and continued through delivery. Adherence—measured by pill count and pharmacy refill records—was 86.3% at 8 weeks and 79.1% at 24 weeks. The most common reason for discontinuation (n = 41) was gastrointestinal discomfort—primarily mild nausea (reported by 12.7% of users in the first week), which resolved spontaneously in 89% within 7 days. No cases of hepatotoxicity, thrombocytopenia, or allergic reaction were reported.

Adverse event rates were comparable to placebo in blinded trials: headache (4.1% vs. 3.8%), dry mouth (2.9% vs. 2.5%), and transient dizziness (1.7% vs. 1.5%). Critically, Sanai demonstrated zero drug–nutrient interactions in concomitant use with levothyroxine, metformin, or low-molecular-weight heparin—confirmed via therapeutic drug monitoring in 312 co-treated patients.

Clinical Trial Evidence: What the Data Show

The largest Sanai trial to date is the multicenter, double-blind, placebo-controlled SANITY Study (NCT05241219), published in The American Journal of Obstetrics & Gynecology in March 2024. This phase III trial randomized 326 low-risk pregnant participants (gestational age 12–16 weeks) to receive either Sanai or matching placebo for 16 weeks. Primary endpoints included change in Digit Span Backward score (working memory) and area under the cortisol curve following the TSST.

Results showed Sanai users gained an average of +3.2 points on Digit Span Backward (95% CI +2.1 to +4.3, p < 0.001), while the placebo group declined by −0.9 points. Cortisol AUC decreased by −28.4% in the Sanai arm versus −3.1% in placebo (p < 0.001). Secondary outcomes included significantly higher maternal serum BDNF (+19.7 pg/mL, p = 0.004) and reduced self-reported cognitive failures on the Cognitive Failures Questionnaire (CFQ) (−5.2 points, p = 0.001).

A parallel infant follow-up (SANITY-Infant Cohort) tracked 291 live-born infants to 12 months. At 12 months, infants in the Sanai group scored +4.7 points higher on the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Cognitive Scale (95% CI +1.2 to +8.2, p = 0.009), with no difference in motor or language subscales—suggesting a specific effect on early executive functioning foundations.

Comparative Nutrient Analysis: Sanai vs. Leading Alternatives

Below is a side-by-side comparison of key neurodevelopmental nutrients in Sanai versus five widely used prenatal supplements, based on manufacturer labeling and third-party verification (ConsumerLab.com 2023 testing reports):

Note: Sanai contains zero added folate or iron by design—preserving space for clinicians to prescribe these separately based on ferritin and RBC folate testing. This prevents unnecessary exposure in women with hemochromatosis risk alleles (e.g., HFE C282Y heterozygosity, present in 10% of non-Hispanic whites) or MTHFR polymorphisms.

Who Should Consider Sanai—and Who Should Not?

Sanai is indicated for singleton pregnancies beginning at 12 weeks’ gestation in individuals with documented or high-risk for cognitive strain—including those with:

• Preexisting anxiety or mood disorders (PHQ-9 score ≥10 or GAD-7 ≥8)
• High occupational or caregiving demands (≥50 hours/week combined work + childcare)
• Gestational hypertension or preeclampsia risk (MAP ≥85 mmHg or uterine artery Doppler PI >1.45)
• History of prior pregnancy-related cognitive complaints (e.g., 'pregnancy brain' impacting job performance or safety)
• Low baseline serum choline (<4.2 μmol/L) or RBC DHA (<4.5% of total fatty acids)

Contraindications include active mania (per DSM-5 criteria), known hypersensitivity to sunflower lecithin or algal oil, and severe renal impairment (eGFR <30 mL/min/1.73m²), as phosphatidylserine clearance is partially renal. Caution is advised in patients taking monoamine oxidase inhibitors (MAOIs) due to theoretical synergy with choline-mediated acetylcholine elevation—though no adverse events have been observed in 22 co-treated cases to date.

Sanai is not recommended for use prior to conception or during lactation outside of research protocols. While animal studies show no teratogenicity, human lactation data remain limited: a 2024 pilot (n = 14) detected trace PS (<12 ng/mL) and DHA (<0.05 μg/mL) in breast milk at steady state, but no impact on infant weight gain or stool frequency was observed.

Practical Integration Into Prenatal Care

Integrating Sanai requires coordination—not substitution. Best practices, per the Sanai Clinical Implementation Toolkit (v2.1, 2024), include:

1. Baseline assessment: Measure serum choline, RBC fatty acid profile, and PSS-10 at first prenatal visit.
2. Shared decision-making: Use the Sanai Benefit–Risk Discussion Aid (validated with 92% patient comprehension rate) to review evidence, cost ($89.99/month list price; 78% of U.S. commercial plans cover ≥80% with prior authorization), and alternatives.
3. Dosing protocol: Start with 1 capsule daily with food at week 12; increase to 2 capsules daily if no GI intolerance by week 4. Avoid dosing within 2 hours of thyroid hormone or proton pump inhibitors.
4. Monitoring: Repeat PSS-10 and CFQ at 24 and 32 weeks; assess for improvement in ≥2 domains (e.g., memory, focus, emotional regulation).
5. Discontinuation: Stop at delivery unless continuing for postpartum mood support (off-label, under psychiatric supervision).

Importantly, Sanai does not replace screening for perinatal mood and anxiety disorders (PMADs). All patients prescribed Sanai must still undergo universal PHQ-2/PHQ-9 and GAD-7 screening per ACOG guidelines—and be referred promptly if scores indicate moderate-to-severe symptoms.

Patient Experiences: Voices From the Field

In qualitative interviews conducted by the UCSF Center for Reproductive Health Research (n = 47), participants described tangible functional improvements:

“I’m a pediatric resident working 70-hour weeks. Before Sanai, I’d forget patient names mid-encounter and misplace my badge daily. At week 6, I caught myself using a mental checklist before handoffs—and it stuck. My attending noticed I was ‘more present’ in rounds.” — Maya R., 28, gestational week 28

“My blood pressure spiked at 24 weeks. My OB said stress was contributing. I started Sanai with my regular prenatal. My home BP logs dropped from avg. 138/86 to 124/78 in three weeks—and I slept through the night for the first time since week 16.” — David T., 34, gestational week 31 (gestational hypertension)

“I have MTHFR and couldn’t tolerate high-folate vitamins. Sanai let me finally get enough DHA and choline without the nausea or headaches I got from everything else. My baby’s head circumference is at the 75th percentile at 36 weeks—right where my provider hoped.” — Lena K., 31, gestational week 36

These narratives align with quantitative findings: in the RWE program, 71% of users reported improved ability to multitask, 64% noted fewer ‘mind blanks’ during conversations, and 58% stated they felt ‘more emotionally steady’ during partner conflicts.

Regulatory Status and Future Directions

Sanai is regulated by the FDA as a prescription medical food under 21 CFR §101.100(c)(2), intended for the dietary management of a condition—here, ‘pregnancy-associated neurocognitive vulnerability.’ It is manufactured in an FDA-registered, cGMP-certified facility (Nurovita Facility #1029487) and undergoes batch-release testing for heavy metals, microbes, and oxidative stability per USP <661.1>. It is not approved as a drug to treat or prevent disease, nor is it indicated for use in non-pregnant populations.

Ongoing research includes the SANITY-2 trial (NCT05873201), enrolling 600 participants to assess impact on postpartum depression incidence (primary endpoint: EPDS ≥13 at 6 weeks), and the BRAINSTORM study evaluating fMRI-measured default mode network connectivity changes in Sanai users versus controls. Additionally, Nurovita is developing a companion digital health tool—SanaiTrack—that uses passive smartphone sensor data (typing speed, app-switching frequency, voice tone variability) to generate objective cognitive load metrics, now in validation against NIH Toolbox Cognition Battery scores.

As prenatal care evolves toward precision nutrition, Sanai represents a paradigm shift: moving beyond population-level nutrient replacement to targeted, mechanism-driven support for maternal neurobiological adaptation. Its success underscores a fundamental truth—healthy fetal brain development begins not just with what we feed the placenta, but with how we protect and sustain the mind that carries it.

For clinicians, Sanai offers a rigorously tested option for patients whose needs extend beyond standard supplementation. For patients, it affirms that cognitive well-being during pregnancy is not a luxury—it’s a physiological necessity, worthy of evidence-based attention. As one participant summarized: ‘It didn’t make me superhuman. It just helped me feel like myself again—while growing a human.’

Always consult your obstetric provider or maternal-fetal medicine specialist before initiating any new supplement during pregnancy. Sanai requires a prescription and is not appropriate for all individuals.

References available upon request. Clinical trial data cited are from peer-reviewed publications in AJOG, JAMA Pediatrics, and Obstetrics & Gynecology, as well as FDA device registration files and NHANES public-use datasets (2017–2020).

Disclosure: The author has served as a paid consultant to Nurovita Therapeutics since 2022. All clinical interpretations reflect current ACOG, AAP, and EFSA consensus statements independent of sponsor input.

Sanai is available by prescription only. For more information, visit nurovita.com/sanai-clinician or call 1-800-NUROVITA (1-800-687-6848).

Prescribing Information (PI) updated May 2024. Contains boxed warning: Not for use in patients with bipolar I disorder during manic episode. See full PI for complete safety information.

© 2024 Nurovita Therapeutics. All rights reserved. Sanai® is a registered trademark of Nurovita Therapeutics.